Yael Capital

Yael Capital (雅亿资本) is a Chinese investment fund that shows up in elsewhere's corpus almost exclusively as a biotech co-investor alongside 5Y Capital: it followed on in PAM2L Biotechnologies' 100M+ RMB Pre-A round in early 2023 , joined the angel+ round of cancer drug developer Signet Therapeutics in 2021 , backed a microbiome drug company's Series B+ in 2020 , and was an early backer of ReviR Therapeutics (founded 2021), continuing to add to its $30M Series A in July 2024 . The pattern is consistently early-stage life sciences, usually in a follow-on role next to larger leads. Beyond these deal appearances — founding date, team, fund size — elsewhere's corpus does not profile the firm itself.